Compare Cassava Sciences Inc (FLNA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Teradyne, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Teradyne, Inc. trades at $407.46 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 1582.2× Cassava Sciences Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Teradyne, Inc. for 37 Days on average.
| FLNA | TER | |
|---|---|---|
Market Cap | $39.40M | $62.34B |
Volume | 759,018 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $4.64 | $483.84 |
52-Week Low | $0.68 | $132.05 |
Typical Hold Time | 37 Days | 37 Days |
Enterprise Value | -$43.28M | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with 59.24% gross margins and consistent earnings beats, including Q2 2026 EPS of $2.47 versus $2.09 expected. Recent product launches like Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand.
TER offers compelling growth potential with 61% analyst buy ratings and a $461.50 price target representing 12% upside. However, elevated valuations (P/E 56.56) and cyclical semiconductor exposure present risks. The stock's outlook remains positive driven by AI infrastructure spending and expanding test portfolio, though investors should monitor competitive pressures and industry demand cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
